A guide to current therapies for managing Parkinson's disease: Clinical options, risks, and treatment planning

This guide to current therapies for managing Parkinson's disease examines the medicines, rehabilitation approaches, and advanced treatments used to address motor and nonmotor symptoms. Treatment is individualized because Parkinson's disease progresses differently among patients, and current therapies primarily improve symptoms rather than stop the underlying neurodegeneration. 1

How treatment planning is individualized

Parkinson's disease is a progressive neurological disorder associated with degeneration of dopaminergic neurons and accumulation of alpha-synuclein in Lewy bodies. Common motor features include bradykinesia, resting tremor, rigidity, and postural instability, while constipation, sleep disturbance, depression, cognitive decline, and autonomic dysfunction may occur before or alongside movement symptoms. These motor and nonmotor features influence medication selection, referral decisions, and the timing of rehabilitation or procedural care. 2

Clinical planning also considers age, cognitive status, symptom severity, daily responsibilities, impulse-control risk, swallowing ability, treatment goals, and the presence of medication-related fluctuations. The American Academy of Neurology guidance reaffirmed in February 2025 indicates that levodopa provides greater motor benefit than dopamine agonists or MAO-B inhibitors, making levodopa the preferred initial treatment for many patients, particularly those older than 60. 3

Levodopa and other dopamine-based medicines

Levodopa combined with carbidopa remains the most effective symptomatic treatment for Parkinson's motor symptoms. Carbidopa reduces peripheral conversion of levodopa, allowing more of the medicine to reach the brain and reducing peripheral adverse effects. Immediate-release tablets are commonly adjusted according to response, while extended-release formulations are used when longer coverage is clinically appropriate. Treatment decisions depend on functional impact rather than a fixed disease stage or universal starting schedule. 3

Dopamine agonists such as pramipexole and ropinirole stimulate dopamine receptors and may be considered in younger patients with mild symptoms, especially when cognitive impairment and impulse-control risks are absent. Their possible problems include sleepiness, hallucinations, low blood pressure, and compulsive behaviors, so monitoring is important. MAO-B inhibitors such as rasagiline and selegiline can be used alone for mild symptoms or as adjuncts, while medication interactions and neuropsychiatric effects require clinical review. 8

Managing wearing-off, fluctuations, and dyskinesia

With continued levodopa treatment, some patients develop wearing-off, in which benefit fades before the next dose, or unpredictable changes between ON and OFF states. COMT inhibitors, including entacapone and opicapone, extend levodopa exposure by reducing peripheral breakdown. Other adjunctive options include the MAO-B inhibitor safinamide and the adenosine A2A antagonist istradefylline. These medicines can improve coverage but may introduce dyskinesia, hallucinations, sleep disturbance, or other adverse effects. 3

Dyskinesia refers to involuntary movements that commonly occur when levodopa benefit is strongest. Amantadine, particularly its extended-release formulation, is identified as the only FDA-approved treatment specifically for levodopa-induced dyskinesia in the supplied treatment overview. Dose timing, reduction of individual levodopa doses, or changes in adjunctive medicines may also be considered. Amantadine can cause confusion, hallucinations, ankle swelling, or livedo reticularis, making age, kidney function, and cognition relevant to eligibility. 3

Nonmotor symptoms and rehabilitation

Medication plans must address symptoms beyond movement because sleep problems, depression, constipation, urinary or blood-pressure dysfunction, speech changes, swallowing difficulty, and cognitive decline can substantially affect daily function. Management is symptom-specific and may involve medication review, psychiatric or sleep assessment, bowel strategies, swallowing evaluation, and safety planning. Anticholinergic drugs may reduce tremor in selected younger patients, but their cognitive and autonomic effects generally make them unsuitable for many older adults. 1

Physical, occupational, and speech therapies are core components of comprehensive care. Physical therapy can focus on gait, balance, transfers, mobility, and fall prevention; occupational therapy addresses dressing, home safety, and daily activities; and speech therapy can address reduced voice volume and swallowing problems. Exercise is identified as an important management strategy across disease stages, although the appropriate program depends on balance, cardiovascular health, cognition, and functional ability. 1

Advanced medication delivery

When oral medicines produce substantial OFF time or unpredictable absorption, device-aided delivery may provide more continuous dopaminergic stimulation. Options described in current treatment reviews include extended-release oral levodopa, inhaled levodopa for selected intermittent OFF episodes, apomorphine rescue injections, intestinal levodopa gel, and subcutaneous foslevodopa/foscarbidopa infusion. These approaches differ in administration method, monitoring requirements, training needs, and adverse-effect profile, so they are generally assessed by movement-disorder specialists. 6

Infusion therapies may reduce OFF time and improve ON time, but they require ongoing equipment management and can cause infusion-site reactions. Apomorphine may be delivered by subcutaneous or sublingual routes for motor fluctuations, with nausea, low blood pressure, sleepiness, and injection-related issues among considerations. Device-aided treatments do not remove the need for follow-up, medication adjustment, caregiver support, or evaluation of cognition, gait, balance, and nonmotor symptoms. 5

Procedural therapies and future directions

Deep brain stimulation uses implanted electrodes connected to a pulse generator to modulate selected brain circuits. It can improve medication-responsive tremor, rigidity, bradykinesia, and motor fluctuations in appropriately selected patients, but it does not reliably correct cognitive decline, medication-resistant balance impairment, or every nonmotor symptom. Selection requires assessment of diagnosis, levodopa responsiveness, cognition, psychiatric stability, surgical risk, and the patient's ability to attend programming and maintenance visits. 5

Magnetic resonance-guided focused ultrasound is incisionless and has approved targets that include the ventral intermediate nucleus of the thalamus, globus pallidus pars interna, and, more recently, the pallidothalamic tract, with benefits and adverse effects varying by target. Emerging approaches include adaptive or closed-loop stimulation, remote programming, low-intensity ultrasound for temporary blood-brain barrier opening, and stem-cell-derived dopaminergic grafts. Disease-modifying therapies targeting alpha-synuclein, mitochondrial dysfunction, inflammation, or protein aggregation remain investigational because definitive clinical benefit has not been established. 4

Risks, monitoring, and treatment expectations

No current therapy reverses established Parkinson's disease or reliably halts its progression. Benefits must therefore be balanced against hallucinations, confusion, sleepiness, low blood pressure, impulse-control disorders, dyskinesia, surgical complications, device problems, and changing medication response. Regular review is necessary because treatment that is appropriate during mild disease may become unsuitable as cognition, gait, swallowing, autonomic symptoms, or caregiver circumstances change. 7

Patients and families should expect treatment to evolve through structured follow-up rather than a single permanent prescription. Clinicians typically assess motor response, OFF periods, involuntary movements, falls, cognition, mood, sleep, blood pressure, swallowing, and medication adherence. Advanced therapies require eligibility assessment, informed discussion of risks and maintenance, and access to specialized programming or infusion support. Research continues, but current care remains centered on individualized symptom control, rehabilitation, safety, and quality of life. 1

Sources

1. Clinical Management of Parkinson's Disease: Features, Diagnosis, and Principles of Treatment, Cold Spring Harbor Perspectives in Medicine
2. Parkinson Disease, StatPearls, NCBI Bookshelf
3. Parkinson's Disease Medications, Parkinsons.org
4. Current and emerging drugs for Parkinson's disease, Frontiers in Pharmacology
5. Advanced Therapeutics in Parkinson's Disease: What's New?, Current Neurology and Neuroscience Reports
6. Recent Developments in the Drug Treatment of Parkinson's Disease, Drugs
7. Parkinson's Disease: Conventional Pharmacotherapy, Drug Delivery Innovations, and Emerging Therapeutic Targets, Brain Sciences
8. A Review of the Recent Advances in the Pharmacological Management of Parkinson's Disease, Cureus